The rationalisation of goods and services tax (GST), announced on Wednesday, directly lowers the cost of everyday medical consumables, and also high-end therapies in oncology and rare diseases, helping reduce out-of-pocket patient expenditure and better adherence to medication.
The country's largest carmaker Maruti Suzuki India expects auto sales to bounce back to the glory days of 7 per cent growth by FY 27, helped by the proposed GST rate cut which is expected to bring down car prices by 3.5 to 8.5 per cent.
'Despite assurance from China, none of the companies have received supplies from Chinese sellers.'
An airport operator will be responsible for maintaining overall service standards at an airport, including those delivered by third-party service providers, under new rules being framed by the Airports Economic Regulatory Authority (AERA), its chairman SKG Rahate told aviation stakeholders at a meeting on Wednesday
'The petrol lobby is very rich and strong.'
As the potential threat of a steep 200 per cent tariff on pharmaceutical imports hangs in the air, analysts and industry insiders feel that focus on exports to non-US regions as well as domestic market will increase as a long-term trend. US President Donald Trump told CNBC's Squawk Box in the first week of August that planned tariffs on import of pharmaceutical products to the US could eventually reach up to 250 per cent.
Electric vehicle (EV) manufacturers breathed a sigh of relief after the GST Council on Wednesday night retained the concessional 5 per cent rate on EVs, though they now face competition from small petrol and diesel cars, which will attract a lower 18 per cent levy.
Spreading risks in sourcing raw materials for electric vehicle (EV) manufacturing is "very critical" and the government can play a key role by enabling access to these from multiple locations worldwide, said Vivek Srivatsa, chief commercial officer at Tata Passenger Electric Mobility, on Friday while stressing the need for faster localisation, especially of batteries.
If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.
Qualcomm has partnered with eyewear brand Lenskart to build glasses using its Snapdragon XR chipsets, which allow for on-device AI processing and spatial computing.
India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.
Shailesh Jejurikar has 'always made an effort to stay close to his roots.'
Analysts believe Tesla will first focus on building the Model Y brand before expanding -- both in terms of volume and models.
The National Pharmaceutical Pricing Authority will monitor how companies are increasing prices of non-scheduled drugs.
In her letter to the Sona BLW board, Rani Kapur said documents executed by her at a time of "mental and emotional vulnerability" were being misused.
The DGCA has issued four showcause notices to Air India over repeated violations of cabin crew deployment, training lapses, rest regulations, and operational oversight that compromise flight safety.
'In the inspections, no issues were found with the said locking mechanism.'
The growing rift between MSIL and rival automakers has complicated the government's efforts to finalise the CAFE norms.
'Who tried engine relight?' 'If the first officer was the one flying at takeoff, the captain may have taken control immediately post-thrust loss.' 'But the AAIB report doesn't clarify any of this.'
Siam argues that a 2040 ban could destabilise ongoing and future investments and threaten millions of jobs in the automotive value chain.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances